Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pituitary Neoplasms 16Neuroendocrine Tumors 15Multiple Endocrine Neoplasia Type 1 9Inflammation 4Acromegaly 4Sexual Dysfunction, Physiological 3Pheochromocytoma 3Obesity 3Neoplasms 3Gastro-enteropancreatic neuroendocrine tumor 3Thyroid Cancer, Papillary 2Prostatic Neoplasms 2Pituitary Diseases 2Paraganglioma 2Pain, Postoperative 2Carcinoid Tumor 2Adrenal Gland Neoplasms 2Zollinger-Ellison Syndrome 1Vitamin D Deficiency 1Serotonin Syndrome 1Pituitary ACTH Hypersecretion 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Pain 1Neuroendocrine Tumour With Carcinoid Symptoms 1Multiple Endocrine Neoplasia 1Meningioma 1Melanoma 1Medulloblastoma 1Lung Neoplasms 1

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Pancreatic Neuroendocrine Tumors × Endocrine × Clear all
NCT02842749 2025-02-10

Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China

Novartis

Phase 4 Completed
61 enrolled 9 charts
EndocrineGastrointestinalNET

Pancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡